GenSight Biologics
Clinical-stage biotechnology company developing gene therapies for retinal diseases and central nervous system disorders, with lead product LUMEVOQ for Leber hereditary optic neuropathy.
Notes
GenSight Biologics is a clinical-stage biotechnology company focused on developing gene therapies for severe retinal and optic nerve diseases. The company's lead product LUMEVOQ (lenadogene nolparvovec) is designed to treat Leber hereditary optic neuropathy (LHON), a rare mitochondrial genetic disease that causes rapid vision loss.
GenSight was founded in 2012 and is headquartered in Paris, France. The company is listed on Euronext Paris (ticker: SIGHT). LUMEVOQ received conditional marketing authorization in Europe in 2024 for the treatment of LHON caused by the ND4 mutation.
The company also develops optogenetics-based approaches (GS030 project) to restore vision in patients with retinitis pigmentosa who have lost photoreceptor function.
Team
- Bernard Gilly - Co-founder & CEO
- LinkedIn: linkedin.com/in/bernardgilly
- José-Alain Sahel, M.D. - Co-founder & Chief Scientific Officer
- Barrett Katz, M.D. - Chief Medical Officer
Additional Research Findings
- Founded in 2012, based in Paris, France
- Listed on Euronext Paris (ticker: SIGHT)
- LUMEVOQ: gene therapy for Leber hereditary optic neuropathy (LHON)
- Received European conditional marketing authorization (2024)
- GS030 optogenetics program for retinitis pigmentosa
- Partner: Institut de la Vision (Paris)
- Raised over €200 million in equity financings
- Collaborations with academic research centers
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |